Compare · ANTX vs AZN
ANTX vs AZN
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 1231.8x ANTX ($213.6M).
- Over the past year, ANTX is up 393.0% and AZN is down 9.9% - ANTX leads by 402.9 points.
- AZN has been more active in the news (14 items in the past 4 weeks vs 6 for ANTX).
- AZN has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- AstraZeneca PLC
- Price
- $5.64+0.62%
- $169.66+1.75%
- Market cap
- $213.6M
- $263.10B
- 1M return
- +14.62%
- -0.09%
- 1Y return
- +393.01%
- -9.89%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2026
- News (4w)
- 6
- 14
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest ANTX
- AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
- Director Readnour Robin Shane sold $212,702 worth of shares (35,402 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Zakrzewski Joseph S gifted 405,880 shares (SEC Form 4)
- SEC Form 10-Q filed by AN2 Therapeutics Inc.
- AN2 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
- Director Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)
- Director Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)
- Director Martin Patricia A. was granted 766 shares, increasing direct ownership by 4% to 18,863 units (SEC Form 4)
- Officer Eizen Joshua M sold $24,803 worth of shares (5,945 units at $4.17), decreasing direct ownership by 3% to 206,554 units (SEC Form 4) to satisfy tax liability
Latest AZN
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial